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cope with forgetfulness, specifically employing strategies to overcome busyness 
in schedules, being away from home and tiredness.
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OBJECTIVES: The study aimed to assess the pattern of traditional medicine(TM) 
use and its impact on antiretroviral therapy (ART) adherence among HIV patients 
in Addis Ababa, Ethiopia. METHODS: A cross-sectional study was conducted 
among HIV patients on ART in Addis Ababa public ART clinics, from September 
to October 2013. The study population consisted of 845 HIV patients who were on 
ART at least for six months, selected by systematic sampling technique from nine 
randomly selected clinics. Data were collected by trained health professionals 
through face-to-face interview of patients, using pre-tested questionnaire. Data 
were entered to Epi-info version 7 and analyzed by SPSS version 16. Logistic regres-
sion was used to assess the impact of TM use on ART adherence. RESULTS: Eight 
hundred forty-five patients were included in the study, 572 (67.7%) of which were 
females. A third (33.2%) of the patients were TM and ART concomitant users. Most 
frequently used TM were Alium sativum (34%) and Ocimum lamifolia (28%); mainly 
for the purpose of managing HIV/AIDS related symptoms (61.2%). Most (68.7%) 
of the patients were using TM without consulting health professionals. Factors 
independently associated with concomitant TM and ART use were perceived qual-
ity of service in ART clinics (poor vs good, AOR 2.35; 95% CI 1.78-3.44), number of 
ART side effects reported (≥ 3 vs ≤ 1, AOR 2.61 95%CI 1.53-5.47) and self-perceived 
health status (poor vs good, AOR 2.14; 95% CI 1.62-6.31). Concomitant TM and ART 
use had statistically significant association with poor ART adherence (AOR 3.15; 
95% CI 2.32-6.32). CONCLUSIONS: The study revealed that many patients used TM 
concomitant to ART. Since TM use among the patients was found to impact their 
ART adherence and because of the possibility for interaction, patients should be 
advised to consult their health care providers when they need to take TM while 
on ART.
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OBJECTIVES: The outbreak of Ebola in 2014 has been the largest in history, affecting 
multiple countries in West Africa and cases were diagnosed within the United States 
as well. This study uses the framework of the Health Belief Model and aims to under-
stand the perceptions of a cohort of individuals in Houston, Texas towards this out-
break, measured as the likelihood of performing preventive behaviors. METHODS: 
This is a prospective, cross sectional study design with an anonymous, self-admin-
istered survey based on the constructs of the Health Belief Model. Individuals aged 
18 or older were requested for their participation by convenience sampling at public 
places in Houston, Texas between 4th November and 28th December 2014. The 
variables measured were perceived susceptibility, perceived severity, perceived 
threat, knowledge about Ebola, self-efficacy and existing health belief. For statisti-
cal analysis the Health Belief Model based statements in the survey were grouped 
as per domain, the scores were summed up to give the variable values, which were 
tested in a multiple regression model. RESULTS: A total of 283 participants aged 
18 to 74 (Mean: 34.5±12.7, 54.8% male) completed the survey. Of the Health Belief 
Model constructs tested for, perceived susceptibility (p= 0.0366), perceived threat 
(p< 0.0001), educational level (p= 0.0470), actively following the news (p= 0.0015) 
and existing health belief (p= 0.0003) were predictors of the likelihood to perform 
preventive health behaviors. CONCLUSIONS: The Health Belief Model adequately 
predicted public perception regarding their belief about the threat of the disease 
and susceptibility towards the disease. Educating the public about the actual risks 
of Ebola in United States through various media can elicit appropriate behavior in 
any future cases of outbreak within the United States.
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OBJECTIVES: We sought to identify pneumonia knowledge among participants in the 
Pharmacist’s Pneumonia Prevention Project (PPPP), a community-based education 
and vaccination program administered to older Philadelphians in 2014. METHODS: 
Participants were aged 50+, cognitively intact, English speaking and recruited from 
senior centers and churches with a predominantly black population in Philadelphia. 
This analysis reports baseline data which were collected prior to delivery of PPPP. 
Knowledge and awareness of pneumonia was assessed with a 22-item question-
naire encompassing the following domains: susceptibility to infection, symptoms 
of disease, severity of illness, and vaccination with an emphasis on vaccine efficacy, 
safety, and eligibility. RESULTS: 203 individuals were enrolled, of whom 75% were 
female and 80% were black, with a mean age of 74(SD 9) years. Additionally, 148 
(73%) participants had at least a high school education. Of the 203 participants, 97 
(48%) described pneumonia in their own words, but only 33 of these (34%) correctly 
described it as an infection in the lungs. When asked about the best way to prevent 
pneumonia, 47% of participants reported answers other than vaccination. Compared 
to women, more men were unaware of the individuals who were at risk of getting 
pneumonia. Specifically, 81% of men did not think that the very young were at risk of 
getting the disease (vs. 56% of women; p= 0.032). Additionally, 76% of men were una-
ware that patients with a low immune system were at risk for pneumonia (vs. 39% of 
women; p= 0.002). CONCLUSIONS: Findings revealed critical knowledge gaps about 
pneumonia, underscoring the need for educational approaches which resonate with 
this study is to determine the cost-effectiveness of a PCV13 vaccination program 
versus a PPSV23 program in high risk adults 18 years old and over with a coverage 
of 100% and in healthy adults 65 years old with a coverage of 90%, in the Chilean 
Health System. METHODS: A cost/utility study was performed using a Markov 
model (population data for a time horizon of 10 years). Utilities and epidemio-
logical data like incidence, mortality, and consequences of pneumococcal disease 
were obtained from Chilean, Latin American and International published literature. 
Vaccine’s efficacies were taken from literature for PPSV23 and from the Community-
Acquired Pneumonia Immunization Trial in Adults (CAPITA) for PCV13. Direct and 
indirect costs were considered and were obtained from FONASA, the Chilean Public 
Health Insurance. Vaccine’s costs and quality-adjusted life of years (QALYs) were 
determined and compared. RESULTS: With a PCV13 vaccination program, 107 cases 
of bacteremia, 13 of meningitis, 6,706 of inpatient pneumonia, 4,509 of outpatient 
pneumonia and 1,189 deaths were avoided compared with PPSV23 program. The 
total cost over the 10 year period studied, and for the total population of 12,773,697 
people, was $1,994,404 for PCV13 and $2,026,510 for PPSV23. For PCV13, QALYs 
were 11,484,554 and for PPSV23, QALYs were 11,479,124, thus the Incremental Cost/
Effectiveness Ratio (ICER) was dominant for PCV13, and these results do not vary 
with sensitivity analysis on high impact variables. CONCLUSIONS: A PCV13 vac-
cination program is dominant over a PPSV23 program, and a population program 
with PCV13 would save public health expenses and reduce morbidity, mortality 
and disability in Chilean adults over 18 years old. These results appear to be robust 
under a variety of sensitivity analysis.
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OBJECTIVES: Human immunodeficiency virus (HIV) treatment guidelines recom-
mend target adherence levels of 95% and suggest that treatment be postponed in 
patients at risk of poor adherence. Little objective guidance is provided to clini-
cians for identifying such patients. We applied an optimal data analysis (ODA) 
paradigm to create predictive models for adherence in a national cohort of United 
States veterans using electronic medical records (EMRs) by maximizing predic-
tive accuracy. METHODS: Quarterly adherence to antiretroviral agents was calcu-
lated as the proportion of days covered (PDC) with 3 or more antiretroviral agents 
from 2 or more drug classes. A hierarchical decision tree was built to predict 
patient adherence at different adherence thresholds of 75%, 80%, 85%, 90% and 
95%. The attribute variables included demographics, comorbidities, and disease 
characteristics. Three rules were applied to pick the predictors: 1) at each deci-
sion point, the attribute with the lowest Fisher’s exact p-value was selected; 2) 
leave-one-out jackknife analysis was performed to select a stable attribute; and 
3) dividing a branch of decision tree was stopped if the branch had less than 
15 patients. RESULTS: 3864 HIV patients newly initiated highly active antiret-
roviral therapy in 1998-2006. The mean age of the cohort was 56.3±9.4 year old 
and 98.4% were males. The mean (95% CI) PDC in quarter 1 was 20.9% (41.6-45.0) 
and reached a maximum of 43.3% (20.2-21.7) in quarter 26. The ODA models for 
different thresholds predicted adherence with a C-statistic of 0.58-0.63, a range 
of accuracy defined as no discrimination to poor discrimination. Patients who 
were most non-adherent were those who were < 60 years old, black, treated with 
protease inhibitors and drug abuser. CONCLUSIONS: Using discrete data in the 
EMRs, it is difficult to predict patients at risk of poor adherence. Future work 
should include more complex predictors such as patient adherence to other 
therapies.
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OBJECTIVES: The objectives of this study were to describe and compare adherence 
rates and to determine what factors are related to adherence to therapy among 
patients living with HIV/AIDS receiving Highly Active Antiretroviral Therapy 
(HAART) in a treatment center in Lagos, Nigeria. METHODS: Patients in the study 
were living with HIV/AIDS, 18 years or older, receiving HAART, and had visited 
the clinic between June and July 2012. Adherence was measured using two self-
reported measures: number of doses taken over the past two weeks/number of 
doses provided over the past two weeks and the valid and reliable Morisky scale. 
Barriers, satisfaction with therapy, and sociodemographic and clinical variables 
served as independent variables. Data were collected via self-administered sur-
veys. Descriptive statistics, Pearson’s correlation, McNemar’s test, Pearson’s chi-
square test, analysis of variance, and logistic regression were used to address study 
objectives. RESULTS: The majority of the study sample (N= 361) were between 18 
and 40 (64.9%), female (58.3%), married (64.8%), working (83.8%), and on HAART for 
at least one year (82.0%) while a plurality of the sample had a college education 
(46.5%). Most of the patients (79.5%) reported 100% adherence using two-week self-
recall and 49.6% using the Morisky scale. Both methods used to measure adher-
ence were significantly correlated (rho= 0.476; p< 0.001). The significant (p< 0.01) 
barriers to adherence between those 100% and < 100% adherent were forgetfulness, 
running out of medication, alcohol use, and medication side effects. Multivariate 
logistic regression analysis showed that for every unit increase in the number of 
barriers, patients were 60.8% less likely to be 100% adherent (p< 0.001, OR= 0.392, 
95% CI= 0.295-0.523). CONCLUSIONS: Interventions should target helping patients 
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to elicit preference values for HCV-specific health states from general public par-
ticipants in Australia, Brazil, France, Italy, and Spain. METHODS: HCV health state 
descriptions were based on literature review and clinical expert feedback for the 
following: asymptomatic and symptomatic mild/moderate HCV, compensated cir-
rhosis, five decompensated cirrhosis states (hepatocellular carcinoma, ascites, acute 
and chronic variceal hemorrhage, and hepatic encephalopathy), and liver transplant 
(first year and subsequent years). These descriptions included key HRQoL impacts 
(activities, mood, stigma, cognition, and sleep) associated with each state, and were 
validated by members of the general public. Trained interviewers elicited time 
trade-off preference values (or, utilities) from a general public sample, quantifying 
preferences for each health state on a scale of 0 (dead) to 1 (full health). Mean (95% 
confidence interval) preferences were estimated for each country and adjusted for 
age and sex using beta and generalized linear models. RESULTS: Logical responses 
from 488 participants were included; approximately 50% were male. Mean ages 
ranged from 39.1 (Brazil) to 47.7 (Italy) years. Mean values for asymptomatic mild/
moderate HCV health states ranged from 0.90 (0.88-0.91; Australia) to 0.79 (0.76-
0.81; Brazil); for the acute variceal hemorrhage health state, mean values were 
0.27 (0.24-0.29; France) to 0.39 (0.39-0.42; Italy). Mean preferences for compensated 
cirrhosis ranged from 0.69 (0.33-0.72; Brazil) to 0.77 (0.75-0.79; Australia). Values 
were less than 0.70 for all decompensated cirrhosis states. Age- and sex-adjusted 
beta and generalized linear models showed similar results. CONCLUSIONS: This 
study provides estimates of the quality of life decrement associated with severe 
liver disease health states, from the general public perspective. This information 
is important for understanding the benefit of early treatment to delay disease pro-
gression in patients with HCV.
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OBJECTIVES: Standardized methods to measure symptoms and related patient-
reported outcomes (PRO) in Hospital-Acquired Bacterial Pneumonia (HABP) are 
limited. The purpose of this literature review was to identify signs, symptoms, and 
measurement tools associated with patients’ experience of HABP. The results will 
be used to inform the development of a valid PRO tool for HABP that is consistent 
with the FDA PRO Guidance. METHODS: To identify relevant literature, MEDLINE 
(1946 to 2014) and EMBASE (1988 to 2014) databases were searched individually 
and in combination using terms related to Hospital-Acquired Pneumonia (HAP), 
HABP, signs and symptoms, and patient-reported outcomes. RESULTS: The search 
identified 1384 abstracts. 225 were excluded as duplicates or for missing content. 
1145 abstracts were excluded based on pre-specified criteria. The remaining articles 
were scrutinized for eligibility, resulting in six that met the inclusion criteria. The 
most frequently cited signs and symptoms of HABP were fever, cough, purulent spu-
tum, dyspnea, rales, chest pain, and elevated respiratory rate. No PRO measures for 
assessing HABP signs and symptoms were identified in the literature. Current HABP 
clinical trials have not included end points that directly measure how a patient 
feels and functions. CONCLUSIONS: The HABP literature has historically focused 
on clinical outcomes to evaluate treatment efficacy and there is currently limited 
evidence assessing the impact of antibiotic therapies on symptomatology in HABP 
patients. Endpoints, such as clinical response, clinical cure, and time to event, are 
only indirect measures of treatment benefit and have not been validated. It is essen-
tial to develop reliable, well-defined and clinically relevant endpoints that measure 
tangible benefits for patients in clinical trials of antibacterial drugs in accordance 
with the FDA Guidance for PRO measures and HABP. This literature review is the first 
step in identifying concepts that will be explored further in qualitative interviews 
with HABP patients.
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OBJECTIVES: Pegylated-interferon/ribavirin (PR) is commonly used to treat HCV 
genotype 1 (G1) -infected patients, both as dual therapy or triple therapy, combined 
with a direct-acting antiviral (DAA). PR-based treatments are associated with high 
levels of toxicity and decreased QoL. Adding simeprevir as DAA to PR reduces dura-
tion of PR-therapy and increases significantly the proportion of patients reaching 
viral response (VR). The objective of this analysis was to explore the impact of dura-
tion of PR therapy and of having VR on the level of impairment of QOL and other 
patient-reported outcomes (PRO). METHODS: Longitudinal QoL/PRO outcomes were 
analyzed from three randomized clinical trials comparing PR+simeprevir with PR 
in treatment-naïve HCV-G1 patients: PILLAR (n= 316); QUEST-1 (n= 394) ; QUEST-2 
(n= 391). Early responders in the simeprevir arm were allowed to stop PR-therapy at 
24 weeks, instead of 48 week PR-therapy. A mixed-effects model was fitted, including 
age, gender, baseline fibrosis status, time, treatment interaction between time and 
treatment as covariates, and PR-therapy and viral response as binary time-varying 
covariates (viral load < /≥ 25 IU/ml). A model was fitted by trial for the EQ-5D valu-
ation index (VI) and visual analog scale (VAS), the Fatigue Symptom Severity scale 
(FSS) and the Center for Epidemiologic Studies Depression Scale (CES-D). RESULTS: 
Shortened PR-therapy positively impacted all PRO-endpoints consistently across all 
studies (p-values ranging between < 0.0001 and 0.025). The estimated mean for the 
positive impact on EQ5D-VI were 0.08 (p= 0.0001), 0.05 (p= 0.025) and 0.08 (p= 0.0005) 
this population. Results also suggest that the knowledge gap is greater among males 
than females. This in mind, PPPP includes culturally sensitive elements such as a 
skit developed by community members and small group discussions to engage the 
population in conversations about pneumonia.
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OBJECTIVES: The purpose of this study was to develop a patient-reported out-
come (PRO) instrument to assess Acute Bacterial Skin and Skin Structure Infection 
(ABSSSI) symptoms in patients in clinical trials of antibacterial drugs, consistent 
with FDA PRO Guidance. METHODS: A comprehensive review of the literature and 
interviews with nine US and European clinical experts informed the development 
of a concept elicitation (CE) interview guide, and a hypothetical conceptual frame-
work and disease model exploring patients’ experience with symptoms of ABSSSI. 
CE was based on telephone interviews with 34 patients, after which saturation 
of emergent concepts was reached. Items and response options were generated 
based on the qualitative data and a draft instrument was prepared with input and 
review from an international project team of academic and industry antibacte-
rial experts. Subsequently, cognitive debriefing interviews were conducted with 15 
ABSSSI patients and 3 clinical experts to assess item readability, relevance, com-
prehensiveness, and content validity. Items were edited based on feedback from 
the patients. RESULTS: CE subtypes were evaluated and consisted of 13 (38.2%) 
patients with major abscess, 12 (35.3%) with wound infection, and 9 (26.5%) with 
cellulitis. In terms of severity, the majority (79.4%) of infections were rated as moder-
ate by clinicians. The mean age of patients was 38.8 years; 64.7% male. Symptoms 
were common across all ABSSSI subtypes and supported the saturation of con-
cepts. Items were generated for the PRO Instrument using patient terminology. 
Subsequent cognitive debriefing with patients demonstrated that the items were 
understandable, relevant, and interpreted as intended. CONCLUSIONS: SKINFECT is 
a PRO instrument developed to evaluate ABSSSI patient symptoms and functioning 
in clinical studies with documented evidence of content validity. Qualitative data 
from patients and input from experts formed the basis of the SKINFECT’s structure 
and item pool, and it is now ready for psychometric reliability and validity testing.
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OBJECTIVES: There is a paucity of evidence regarding a well-defined, reliable, and 
feasible method for measuring efficacy outcomes from a patient perspective in 
Community-Acquired Bacterial Pneumonia (CABP) trials. Most CABP studies eval-
uate treatment efficacy on the basis of clinical outcomes; however, there is no 
patient-reported outcome (PRO) to capture additional symptoms of how patients 
feel, function, or survive. The goal of this study was to explore CABP symptoms as 
reported by patients, and to develop a draft PRO instrument designed to compre-
hensively assess these symptoms. METHODS: Concept elicitation was conducted by 
telephone interviews with patients within 10 days of CABP diagnosis. Data was ana-
lyzed using an iterative process to identify themes and concepts and was recorded 
in a saturation grid. Saturation was monitored according to the FDA PRO guidance. 
Using this qualitative data, a draft PRO instrument was prepared. Cognitive debrief-
ing interviews were conducted to assess item readability, relevance, comprehen-
siveness, and content validity. RESULTS: Twenty patients participated in concept 
elicitation interviews. Mean age of the patients was 59.5 years (SD = 18.8, range: 
29-90); 45% were female. The most common symptoms reported included a lack of 
energy or tiredness (n= 18), cough (n= 16), and shortness of breath (n= 16). Nearly 
half the patients also reported fever, chest pain and general aches/pain as well as 
significant impacts on their social (n= 10) and physical functioning (n= 17) related 
to the skin infection. Subsequent cognitive debriefing in 9 patients and 3 clinical 
experts demonstrated that the items were understandable, relevant, and interpreted 
as intended. CONCLUSIONS: Qualitative data from patients and input from experts 
formed the basis of the CABP PRO structure and item pool. These patient-reported 
CABP symptoms were shown to demonstrate content saturation and concept valid-
ity and provide unique information important for both comprehensive evaluation 
of individuals with CABP and evaluation of new antibacterial treatments.
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OBJECTIVES: Limited country-specific data exist on health-related quality-of-life 
(HRQoL) impacts of hepatitis C virus (HCV) infection. The aim of this study was 
